Chronic Pain Clinical Trial
Official title:
Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation (SCS) With High Dose (HD) Stimulation Parameters
Verified date | October 2020 |
Source | MedtronicNeuro |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, single-arm, multi-center study evaluating the efficacy of spinal cord stimulation (SCS) therapy for pain relief using high dose (HD) stimulation parameters delivered to neural targets identified during current commercial trial stimulation procedures. The study will evaluate changes in back and leg pain from baseline to 3, 6, and 12 months.
Status | Completed |
Enrollment | 175 |
Est. completion date | October 21, 2019 |
Est. primary completion date | February 4, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Candidate per labeling for an SCS system as an aid in the management of chronic, intractable low back and leg pain - Presence of low back and leg pain - Moderate to crippled disability due to pain - Stable pain medications for back and leg pain for at least 28 days prior to enrollment - Willing and able to not increase pain medications through the 3-Month visit Exclusion Criteria: - Previously trialed or implanted with stimulator or intrathecal drug delivery system - Current diagnosis of moderate to severe central lumbar spinal stenosis - Major psychiatric comorbidity or other progressive diseases - Serious drug-related behavioral issues - Pregnant or planning on becoming pregnant - Unable to achieve supine position |
Country | Name | City | State |
---|---|---|---|
United States | Lehigh Valley Healthcare Network | Allentown | Pennsylvania |
United States | Saint Luke's Neurosurgical Associates | Bethlehem | Pennsylvania |
United States | Lowcountry Orthopaedics/Coastal Carolina Research Center | Charleston | South Carolina |
United States | The Ohio State University Wexner Medical Center | Columbus | Ohio |
United States | Comprehensive and Interventional Pain Management | Henderson | Nevada |
United States | Carolinas Pain Center | Huntersville | North Carolina |
United States | Pain Consultants of San Diego | La Mesa | California |
United States | Restore Orthopedics and Spine Center | Orange | California |
United States | National Spine and Pain | Oxon Hill | Maryland |
United States | Carilion Clinic Roanoke Memorial Hospital | Roanoke | Virginia |
United States | University of Rochester Neurosurgery Partners Pain Management | Rochester | New York |
United States | Pain Diagnostics and Interventional Care | Sewickley | Pennsylvania |
United States | Carolina Center for Advanced Management of Pain | Spartanburg | South Carolina |
United States | Northwest Pain Care | Spokane | Washington |
United States | Pain Care | Stockbridge | Georgia |
United States | Delaware Valley Pain and Spine Institute | Trevose | Pennsylvania |
United States | Precision Spine Care | Tyler | Texas |
United States | The Pain Management Center | Voorhees | New Jersey |
United States | Center for Interventional Pain and Spine | Wilmington | Delaware |
United States | Michigan Pain Consultants | Wyoming | Michigan |
Lead Sponsor | Collaborator |
---|---|
MedtronicNeuro |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Overall Pain Intensity on the Visual Analog Scale (0-100) | Demonstrate a significant improvement in overall pain intensity as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The change in overall pain intensity is calculated as the Baseline VAS minus the 3-month VAS, where a positive value indicates an improvement (ie, reduction) in pain from Baseline to 3 months. Higher values represent a larger reduction (ie, greater improvement) in pain. The change in overall pain intensity as measured by the VAS can range from -100 (worsening in pain from 0 at baseline to 100 at 3 months) to 100 (improvement in pain from 100 at baseline to 0 at 3 months). It should be noted that while the change in VAS can range from -100 to 100, no subjects had a VAS of 0 at baseline, as the presence of pain was required for eligibility for inclusion in the study. |
Baseline to 3 months | |
Secondary | Overall Pain Efficacy Responder Rate | Characterize the overall pain efficacy responder rate, where the responder rate is the percentage of subjects who experience at least a 50% improvement in overall pain, as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The percent improvement for each subject was calculated as [100*(Baseline VAS - 3-month VAS)/Baseline VAS], where a positive number represents an improvement, and the larger the number the greater the percent improvement. If the percent improvement from baseline to 3 months was at least 50%, the subject was considered a responder. The percentage of subjects who experience at least a 50% improvement in overall pain can range from 0% (no responders) to 100% (all responders). |
Baseline to 3 months | |
Secondary | Low Back Pain Efficacy Responder Rate | Characterize the low back pain efficacy responder rate, where the responder rate is the percentage of subjects who experience at least a 50% improvement in low back pain, as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The percent improvement for each subject was calculated as [100*(Baseline VAS - 3-month VAS)/Baseline VAS], where a positive number represents an improvement, and the larger the number the greater the percent improvement. If the percent improvement from baseline to 3 months was at least 50%, the subject was considered a responder. The percentage of subjects who experience at least a 50% improvement in low back pain can range from 0% (no responders) to 100% (all responders). |
Baseline to 3 months | |
Secondary | Leg Pain Efficacy Responder Rate | Characterize the leg pain efficacy responder rate, where the responder rate is the percentage of subjects who experience at least a 50% improvement in leg pain, as measured by the Visual Analog Scale (VAS). The VAS ranges from 0 (no pain) to 100 (worst pain imaginable). The percent improvement for each subject was calculated as [100*(Baseline VAS - 3-month VAS)/Baseline VAS], where a positive number represents an improvement, and the larger the number the greater the percent improvement. If the percent improvement from baseline to 3 months was at least 50%, the subject was considered a responder. The percentage of subjects who experience at least a 50% improvement in leg pain can range from 0% (no responders) to 100% (all responders). |
Baseline to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|
||
Completed |
NCT05036499 -
PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain
|
N/A |